Daviess County - Indiana Criminal Code 2022

MISCELLANEOUS LAWS

381

being. 16-18-2-194. “Investigational or new drug” defined. “Investigational or new drug,” for purposes of IC 16-42-19, has the meaning set forth in IC 16 42-19-4. 16-18-2-199. “Legend drug” defined. “Legend drug,” for purposes of IC 16-42, means a drug that is: (1) Subject to 21 U.S.C. 353(b)(1); or (2) Listed in the Prescription Drug Product List as:

“Controlled substance,” for purposes of IC 16 42-21, has the meaning set forth in IC 16-42-21 1. 16-18-2-101. “Drug” defined. (a) “Drug,” for purposes of IC 16-42-1 through IC 16-42-4, means the following: (1) Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them. (2) Articles intended for use in the diag nosis, cure, mitigation, treatment, or pre vention of disease in man or other animals. (3) Articles other than food intended to affect the structure or any function of the body of man or other animals. (4) Articles intended for use as a compo nent of any article specified in subdivision (1), (2), or (3). The term does not include devices or their com ponents, parts, or accessories. (b) “Drug,” for purposes of IC 16-42-19, has the meaning set forth in IC 16-42-19-2. 16-18-2-102. “Drug order” defined. “Drug order,” for purposes of IC 16-42-19, has the meaning set forth in IC 16-42-19-3. 16-18-2-103. “Drug sample” defined. “Drug sample,” for purposes of IC 16-42 21, has the meaning set forth in IC 16-42-21-2. 16-18-2-128.5. “Fetal stem cell” defined. (a) “Fetal stem cell” means any of the fol lowing types of stem cells taken from a fetus that was either miscarried or stillborn from any of the following sources: (1) Placenta. (2) Umbilical cord. (3) Amniotic fluid. (4) Fetal tissue. (b) The term does not include any cells that are taken as the result of an abortion. 16-18-2-183.5. “Human embryo” defined. “Human embryo” means a human egg cell with a full genetic composition capable of dif ferentiating and maturing into a complete human

(A) Published in United States Department of Health and Human ServicesApproved Drug Products with Therapeutic Equivalence Evaluations, Tenth Edition, (1990); and (B) Revised in United [States] Department of Health and Human Services, Approved Drug Products with Therapeutic Equivalence Evaluations, Cumulative Supplement to the Tenth Edition, Number 10 (1990).

16-18-2-216. “Manufacturer” defined. (a) “Manufacturer,” for purposes of IC 16 42-19 and IC 16-42-21, means a person who by compounding, cultivating, harvesting, mixing, or other process produces or prepares legend drugs. The term includes a person who: (1) Prepares legend drugs in dosage forms by mixing, compounding, encapsulating, entableting, or other process; or (2) Packages or repackages legend drugs. (b) The term does not include pharmacists or practitioners (as defined in section 288(a) and 288(c) of this chapter) in the practice of their profession. 16-18-2-223. “Mechanical device” defined. “Mechanical device,” for purposes of IC 16 42-19-23, has the meaning set forth in IC 16-42 19-23(a). 16-18-2-281. “Pharmacist” defined. “Pharmacist” means a person licensed by law to practice pharmacy in Indiana.